Clinical Trial Update: Dose-escalation of Rectal Indomethacin for Preventing PEP [Phase 4]

View source ↗

Summary

A Phase 4 dose-escalation trial evaluating rectal indomethacin to prevent post-ERCP pancreatitis; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-ercp Pancreatitis

Drugs mentioned

• Indomethacin (rectal) (indomethacin)

Snippet

Sponsor: The First Affiliated Hospital of Anhui Medical University | Conditions: Post-ERCP Pancreatitis | Phase 4 | Status: NOT_YET_RECRUITING